Histopathological Predictors of Recurrence in Stage III Colon Cancer: Reappraisal of Tumor Deposits and Tumor Budding Using AJCC8 Criteria

被引:29
|
作者
Landau, Michael A. [1 ]
Zhu, Benjamin [1 ]
Akwuole, Frances N. [1 ]
Pai, Reetesh K. [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
关键词
colon cancer; tumor deposit; tumor budding; survival; stage IIl; KRAS; BRAF; MSI; mismatch repair; COLORECTAL-CANCER; PROGNOSTIC-SIGNIFICANCE; VENOUS INVASION; LYMPH-NODES; TNM; IMPACT; ADENOCARCINOMA; CARCINOMA; KRAS;
D O I
10.1177/1066896918787275
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Patients with stage III colonic adenocarcinoma have a spectrum of risk for recurrent disease, and histopathological variables that predict recurrence can help stratify patients into prognostic groups. To identify histopathological predictors of recurrence, we investigated the effect of implementation of the eighth edition of the American Joint Committee on Cancer (AJCC8) staging system definition of tumor deposits and International Tumor Budding Consensus Conference (ITBCC) criteria for tumor budding compared with other known prognostic variables in 256 resected colonic adenocarcinomas, including 150 stage III and 106 stage II tumors. In stage III colon cancer, tumor deposits and high tumor budding were the only independent histological variables that predicted disease recurrence. In a multivariable analysis in stage III colon cancer, tumor deposits and high tumor budding were associated with a 2.2- and 1.5-fold increased risk of developing disease recurrence, respectively (95% CI = 1.1-4,2, P = .02, and 95% CI = 1.1-2.1, P = .01, respectively). The negative prognostic effect of tumor deposits was most pronounced in patients with stage IIIB disease in which tumor deposits were associated with a 3.2-fold increased risk of disease recurrence (95% CI = 1.4-7.1; P = .005). Within the N1 cohort, patients with tumor deposits without concurrent positive lymph nodes (N1c) had a significantly decreased disease-free survival compared with patients with N0 tumors (P < .001) and patients with N1a/b tumors (P = .02). As independent risk factors for recurrence, tumor deposits and high tumor budding are important histopathological variables and should be included as a part of a routine comprehensive pathological risk assessment in stage III colon cancer.
引用
收藏
页码:147 / 158
页数:12
相关论文
共 50 条
  • [31] Tumor budding and poorly-differentiated cluster in prognostication in Stage II colon cancer
    Lee, Victor Wai Kwan
    Chan, Kui Fat
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (03) : 402 - 407
  • [32] Prognostic value of tumor laterality and recurrence risk in patients with stage III colon cancer treated with adjuvant chemotherapy
    Monteiro, A.
    Cunha Pereira, T.
    Felix Soares, R.
    Macedo, F.
    Paulo, J.
    Marques, M.
    Bonito, N.
    Jacinto, P.
    Ribeiro, J.
    Sousa, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S101 - S101
  • [33] Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
    Tie, Jeanne
    Cohen, Joshua D.
    Wang, Yuxuan
    Christie, Michael
    Simons, Koen
    Lee, Margaret
    Wong, Rachel
    Kosmider, Suzanne
    Ananda, Sumitra
    McKendrick, Joseph
    Lee, Belinda
    Cho, Jin Hee
    Faragher, Ian
    Jones, Ian T.
    Ptak, Janine
    Schaeffer, Mary J.
    Silliman, Natalie
    Dobbyn, Lisa
    Li, Lu
    Tomasetti, Cristian
    Papadopoulos, Nicholas
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Gibbs, Peter
    JAMA ONCOLOGY, 2019, 5 (12) : 1710 - 1717
  • [34] Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer
    Zhao, Zhengyi
    Cai, Shangli
    Wang, Zhijie
    JAMA ONCOLOGY, 2020, 6 (06) : 932 - 932
  • [35] Adjuvant chemotherapy in stage II and III colon cancer: the role of the “budding and TILs-(tumor-infiltrating lymphocytes) combination” as tumor-host antagonists
    Corinna Lang-Schwarz
    Balint Melcher
    Theresa Dregelies
    Zahra Norouzzadeh
    Stefanie Rund-Küffner
    Klaus Lang-Schwarz
    Michael Vieth
    William Sterlacci
    International Journal of Colorectal Disease, 2021, 36 : 1765 - 1779
  • [36] Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonists
    Lang-Schwarz, Corinna
    Melcher, Balint
    Dregelies, Theresa
    Norouzzadeh, Zahra
    Rund-Kuffner, Stefanie
    Lang-Schwarz, Klaus
    Vieth, Michael
    Sterlacci, William
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (08) : 1765 - 1779
  • [37] Association between tumor budding grade and T stage as prognostic value for recurrence with high-risk stage II colon cancer: A retrospective study
    Kodama, H.
    Yamaguchi, T.
    Ishizuka, N.
    Yukami, H.
    Aoki, M.
    Miyamoto, T.
    Terazawa, T.
    Kii, T.
    Goto, M.
    Hamamoto, H.
    Osumi, W.
    Yamamoto, M.
    Tanaka, K.
    Okuda, J.
    Higuchi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S223 - S223
  • [38] Tumor budding as an index to identify high-risk patients with stage II colon cancer
    Nakamura, Takatoshi
    Mitomi, Hiroyuki
    Kanazawa, Hideki
    Ohkura, Yasuo
    Watanabe, Masahiko
    DISEASES OF THE COLON & RECTUM, 2008, 51 (05) : 568 - 572
  • [39] Is High-Grade Tumor Budding an Independent Prognostic Factor in Stage II Colon Cancer?
    Kyong Shin, Jung
    Ah Park, Yoon
    Wook Huh, Jung
    Hyeon Yun, Seong
    Cheol Kim, Hee
    Yong Lee, Woo
    Hyung Kim, Seok
    Yun Ha, Sang
    Cho, Yong Beom
    DISEASES OF THE COLON & RECTUM, 2023, 66 (08) : E801 - E808
  • [40] Prognostic impact of tumor budding in stage II colon cancer: A prospective study (SACURA trial).
    Ueno, Hideki
    Ishiguro, Megumi
    Nakatani, Eiji
    Ishikawa, Toshiaki
    Uetake, Hiroyuki
    Murotani, Kenta
    Matsui, Shigeyuki
    Tomita, Naohiro
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Kotake, Kenjiro
    Watanabe, Masahiko
    Mochizuki, Hidetaka
    Teramukai, Satoshi
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35